Heart failure (HF) is the leading cause of morbidity and mortality worldwide and negatively impacts quality of life, healthcare costs, and longevity. Although data on HF in the Arab population are scarce, recently developed regional registries are a step forward to evaluating the quality of current patient care and providing an overview of the clinical picture. Despite the burden of HF in Saudi Arabia, there are currently no standardized protocols or guidelines for the management of patients with acute or chronic heart failure. Therefore, the Heart Failure Expert Committee, comprising 13 local specialists representing both public and private sectors, has developed guidelines to address the needs and challenges for the diagnosis and treatment of HF in Saudi Arabia. The ultimate aim of these guidelines is to assist healthcare professionals in delivering optimal care and standardized clinical practice across Saudi Arabia.

Background The prevalence of cardiovascular disease and its risk factors are rising globally, including in the Kingdom of Saudi Arabia (KSA). The majority of epidemiologic data, however, was obtained from primary care centers or tertiary hospitals, and disease epidemiology in the general population needs to be better defined. Objective: This study aims to determine the prevalence of cardiometabolic risk factors in a random sample of adult volunteers in Jeddah, Saudi Arabia, and their risk for atherosclerotic cardiovascular disease (ASCVD). Materials and Methods This cross-sectional study was based on data from volunteers participating in the “My Heart, My Health” community campaign conducted in a large-scale commercial center in Jeddah, KSA. Participants 20 years of age and above answered a questionnaire containing several risk factors of ASCVD. Anthropometric measurements and blood samples were collected for lipid profile and hemoglobin A1c. Ten-year and lifelong ASCVD risk scores were calculated. Results Eight-hundred seven volunteers participated (390 men and 417 women). The most common risk factor for men was low-high-density lipoprotein cholesterol, which was more prevalent than in women (77.9 vs. 30.3%, p < 0.01). The most common risk factor for women was obesity that was more prevalent than for men (42.6 vs. 36.8%, p = 0.30). The mean ASCVD risk score in 10 years was 8.1% (standard deviation [SD]: 10.5), and the mean ASCVD risk factor optimization % was 2.0% (SD: 2.5). The mean lifelong risk score was 39.5% (SD: 13.9), and the mean ASCVD lifelong risk factor optimization was 6.6% (SD: 2.6). Conclusion This study identified a high prevalence of cardiometabolic risk factors in the Saudi general public visiting a large commercial center in Jeddah, Saudi Arabia. The leading cardiometabolic risk factor is dyslipidemia in men and obesity in women. The 10-year ASCVD risk factor score is modest.

No abstract

The global burden of heart failure has reached epidemic proportions with tremendous health and economic consequences. Sodium glucose cotransporter 2 inhibitors, vericiguat, and omecamtiv mecarbil are novel agents that promise to blunt the high residual risk of heart failure with reduced ejection fraction. We review the vast knowledge base that has rapidly materialized for these agents and is poised to shape the current and future trends and recommendations in heart failure pharmacotherapy.

No abstract

No abstract